|
gptkbp:instanceOf
|
gptkb:drug
gptkb:acetylcholinesterase_inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:ATCCode
|
gptkb:N06DA02
|
|
gptkbp:bioavailability
|
100%
|
|
gptkbp:brand
|
gptkb:Aricept
|
|
gptkbp:CASNumber
|
120014-06-4
|
|
gptkbp:contraindication
|
hypersensitivity to donepezil
|
|
gptkbp:developedBy
|
gptkb:Eisai
|
|
gptkbp:eliminationHalfLife
|
70 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
orally disintegrating tablet
|
|
gptkbp:hasMolecularFormula
|
C24H29NO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
donepezil
|
|
gptkbp:improves
|
acetylcholine levels
|
|
gptkbp:interactsWith
|
gptkb:rifampicin
gptkb:ketoconazole
quinidine
anticholinergics
|
|
gptkbp:IUPACName
|
gptkb:(RS)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
|
|
gptkbp:KEGGID
|
gptkb:D07725
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
inhibits acetylcholinesterase
|
|
gptkbp:MeSH_ID
|
D019695
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children
severe hepatic impairment
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
mild to moderate Alzheimer's disease
severe Alzheimer's disease
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL502
gptkb:DB00843
3152
3041
|
|
gptkbp:riskFactor
|
gastrointestinal bleeding
syncope
bradycardia
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
anorexia
fatigue
insomnia
muscle cramps
|
|
gptkbp:synonym
|
gptkb:E2020
|
|
gptkbp:UNII
|
N9ZZT4V5F5
|
|
gptkbp:usedFor
|
gptkb:Alzheimer's_disease
gptkb:dementia
|
|
gptkbp:bfsParent
|
gptkb:CYP2D6_gene
gptkb:ACHE
gptkb:acetylcholinesterase
gptkb:Aricept
|
|
gptkbp:bfsLayer
|
7
|